Narrow List by Age:
(Refer to Clinical Summary for age requirements)
| Protocol | COG-ARST2031 |
|---|---|
| Cancer Type: | High Risk Rhabdomyosarcoma (HR-RMS) |
| Fast Facts |
COG ARST2031
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
Patients must be ≤ 50 years of age at the time of enrollment.
| Protocol | COG AOST2031 |
|---|---|
| Cancer Type: | Osteosarcoma |
| Fast Facts |
COG AOST2031
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Patients must be < 50 years at the time of enrollment
| Protocol | COG ARST2032 |
|---|---|
| Cancer Type: | Rhabdomyosarcoma |
| Fast Facts |
COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Patients must be ≤ 21 years at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.